Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Quetiapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quetiapine SCHEMBL4283801 | 1.00 | DRD2 (1.00) | DRD2ADRA2ALMNACHRM2HTR1A | |
| Quetiapine SCHEMBL29360153 | 1.00 | DRD2 (1.00) | DRD2ADRA2ALMNACHRM2HTR1A | |
| Quetiapine SCHEMBL4638768 | 1.00 | DRD2 (1.00) | DRD2ADRA2ALMNACHRM2HTR1A | |
| Quetiapine SCHEMBL392703 | 0.99 | DRD2 (0.98) | DRD2ADRA2ALMNACHRM2HTR1A | |
| Quetiapine SCHEMBL2155179 | 0.99 | DRD2 (0.98) | DRD2ADRA2ALMNACHRM2HTR1A | |
| Quetiapine SCHEMBL396057 | 0.99 | DRD2 (0.98) | DRD2ADRA2ALMNACHRM2HTR1A | |
| Quetiapine SCHEMBL1649418 | 0.99 | DRD2 (0.98) | DRD2ADRA2ALMNACHRM2HTR1A | |
| Quetiapine SCHEMBL27866344 | 0.98 | DRD2 (0.96) | DRD2ADRA2ALMNACHRM2HTR1A | |
| Quetiapine SCHEMBL27907990 | 0.98 | DRD2 (0.96) | DRD2ADRA2ALMNACHRM2HTR1A | |
| Quetiapine SCHEMBL2537668 | 0.97 | DRD2 (0.94) | DRD2ADRA2ALMNACHRM2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 31208 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146048-A1 | NOVEL BISINDOLYLMALEIMIDE KINASE INHIBITORS | 4M THERAPEUTICS INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122079853-A | N-substituted indoles and other heterocyclic compounds for the treatment of brain diseases | — | 2026-05-26 | — | — | CN | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| WO-2026102000-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS RELATED TO GLUCOSYLCERAMIDASE BETA 1 DEFICIENCY | VOYAGER THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| EP-0936924-A2 | PHARMACEUTICAL COMPOSITION CONTAINING A 5HT 2C? ANTAGONIST AND A D 2? ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1999-08-25 | — | — | EP | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
| EP-0907364-A1 | PHARMACEUTICAL COMPOSITIONS | ZENECA LIMITED (GB) | 1999-04-14 | — | — | EP | claimed |
| WO-1999006381-A1 | A CRYSTALLINE DIBENZOTHIAZEPINE DERIVATIVE AND ITS USE AS AN ANTIPSYCHOTIC AGENT | ZENECA LIMITED (GB) | 1999-02-11 | — | — | WO | claimed |
| WO-1998043646-A1 | NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS, FOR THE TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | AKZO NOBEL N.V. (NL) | 1998-10-08 | — | — | WO | claimed |
| WO-1998011897-A1 | COMBINATION THERAPY FOR TREATMENT OF PSYCHOSES | ELI LILLY AND COMPANY (US) | 1998-03-26 | — | — | WO | claimed |
| EP-0830864-A1 | Combination therapy for treatment of psychoses | ELI LILLY AND COMPANY (US) | 1998-03-25 | — | — | EP | claimed |
| WO-1998004289-A2 | PHARMACEUTICAL COMPOSITION CONTAINING A 5HT2C ANTAGONIST AND A D2 ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1998-02-05 | — | — | WO | claimed |
| WO-1997045124-A1 | PHARMACEUTICAL COMPOSITIONS | ZENECA LIMITED (GB) | 1997-12-04 | — | — | WO | claimed |